Postmenopausal vaginal atrophy and atrophic vaginitis

American Journal of the Medical Sciences

Volumn 314, Issue 4, 1997, Pages 228-231

  Pandit, Lotika ^a   Ouslander, Joseph G ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Atrophic vaginitis; Estrogen replacement; Postmenopausal; Vaginal atrophy

Indexed keywords

ANTIFUNGAL AGENT; ESTRADIOL; ESTROGEN; ESTRONE; METRONIDAZOLE;

CLINICAL TRIAL; CONFERENCE PAPER; CREAM; DOSE RESPONSE; DRUG DOSAGE FORM; DYSPAREUNIA; DYSURIA; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; GEL; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POLYURIA; POSTMENOPAUSE; QUALITY OF LIFE; STRESS INCONTINENCE; SUBLINGUAL DRUG ADMINISTRATION; SUPPOSITORY; TABLET; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; TRICHOMONIASIS; URGE INCONTINENCE; URINE INCONTINENCE; VAGINA ATROPHY; VAGINA CANDIDIASIS; VAGINA EPITHELIUM; VAGINA FLORA; VAGINITIS;

EID: 0030842630     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199710000-00004     Document Type: Conference Paper

References (28)

1. Eskin BA. The Menopause: Comprehensive Management, 3rd ed. New York: McGraw-Hill, Health Professional Division; 1994; 382.
2. Brown KH, Hammond CB. Obstetrics and gynecology clinics of North America. Urogenital Atrophy. 1997;15(1):13-32.
3. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal women. JAMA. 1983;249:2195-8.
4. Smith P. Estrogen and urogenital tract. Acta Obset Gynecol Scand. 1993; 72(suppl 157):1-26.
5. Kalogeraki A, Tamiolakis D. Cigarette smoking and vaginal atrophy in postmenopausal women. In Vivo. 1996; 10(6):597-600.
6. Dupont A, Dupont P, Cusan L, Tremblay M, Rioux J, Cloutier D, et al. Comparative endocrinology and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas. 1991;13:297-311.
7. Whithead MI, Minandi J, Kitchen Y, Sharples MJ. Systemic Absorption of Estrogen from Premarin Vaginal Cream. In: Cook I; ed. The Role of Estrogen / Progestogen in the Management of Menopause. Lancaster: MTP Press; 1978;63-71.
8. Englund DE, Johanssen EDB. Plasma levels of oestrone, estradiol and gonadotrophins in postmenopausal women after oral and vaginal administration of longrigated equine oestrogens (Premarin) Br J Obstet Gynecol. 1978;85:957-64.
9. Heimer G, Englund DE. Effect of vaginally administered estriol on post-menopasual urogenital disorders: A cytohormonal study. Maturitas. 1992;14:171-9.
10. Englund DE, Victor A, Johanssen EDB. Pharmacokinetic and pharmacodynamic effects of vaginal estradiol administration from Silastic rings in postmenopausal women. Maturitas. 1981;3:125-33.
11. Nash HA, Bache V, Alvarez-Sanchez F, Jackanicz TM, Harmon TM. Estradiol delivery by vaginal rings: Potential for hormone replacement therapy. Maturitas. 1997;26:27-33.
12. Fraser IS, Ayton R, Farrell E, Weisberg E, Darling G, Murkies A. A multicenter Australian trial of low dose estradiol therapy for symptoms of vaginal atrophy using a vaginal ring as delivery. Maturitas. 1995;Dec(suppl 22):S41.
13. Henricksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one year multicenter study of efficacy and safety of a continuous, low dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996;174:85-92.
14. Henricksson L, Stjernquist M, Boquist L, Alander U, Selinus I. A comparative multicenter study of the effects of continuous low dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol. 1994;171:624-32.
15. Nachtigall LE. Clinical trial of estradiol vaginal ring in the U.S. Maturitas. 1995;Dec(suppl 22):S43-7.
16. Barensten R, Van de Weijer PHM, Schram JHN. Continuous low dose estradiol released from a vaginal ring estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol. 1997;71:73-80.
17. Eiermann W. The effect of low dose estradiol in the treatment of atrophic vaginitis: A double blind controlled study. The urogenital estrogen deficiency syndrome. Proc Int Workshop. Copenhagen, November, 1986.
18. Mettler L, Olsen PG. Long term treatment of atrophic vaginitis with low dose estradiol vaginal tablets. Maturitas. 1991;14:23-31.
19. Eriksen PS, Rasmussen H. Low dose 17β estradiol vaginal tablets in the treatment of atrophic vaginitis: A double blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol. 1992;44:137-44.
20. Nilsson K, Heimer GM. Low dose estradiol in the treatment of urogenital estrogen deficiency - A pharmacokinetic and pharmacodynamic study. Maturitas. 1992;15:121-7.
21. Nilsson KE, Heimer GM. Ultra low dose transdermal estrogen therapy in postmenopausal urogenital estrogen deficiency - A placebo-controlled study. Menopause. 1(4):191-7.
22. Felding C, Mikkelson AL, Clausen HV, Loft A, Larsen LG. Preoperative treatment with estradiol in women scheduled for vaginal operation for genital prolapse - A randomized, double blind trial. Maturitas. 1992;15:241-9.
23. Rymer J, Chapman MG, Fogelman I. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas. 1994;18:127-33.
24. Bygdeman M, Swahn ML. Replens versus dienoestriol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259-63.
25. Brandenberg A, Mellstrom D, Samsioe G. Low dose estriol treatment in elderly women with urogenital infection. Acta Obstet Gynecol Scand. 1987;140(suppl):33-8.
26. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329:753-6.
27. Rigg LA, Millanez B, Villaneurs B, Yen SSC. Efficacy of intra-vaginal and intra-nasal administration of micronized estradiol 17β. J Clin Endocrinol Metab. 1997;45:1261-4.
28. Fiet J, Herman M, Witte J, Villette JM, Haimart M, Gourmel B, et al. Postmenopausal concentrations, estrone, FSH and LH and of total urinary estradiol and estrone after a single sublingual dose of estradiol 17β. Acta Endocrinol 1982;101:93-7.